Hangtian Yue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hangtian Yue has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Biyu Yang
State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China
14 shared publications - Deqiang Zhang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications - Han Li
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica
14 shared publications - Hui Xu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications - Lanping Ma
Division of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications - Meiyu Geng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S4 ESI-MS analysis (deconvoluted mass spectra) and DAR calculation. (A) Tras-MTL1. (B) Tras-DXd. (C) Tras-DXd-MTL1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S4 ESI-MS analysis (deconvoluted mass spectra) and DAR calculation. (A) Tras-MTL1. (B) Tras-DXd. (C) Tras-DXd-MTL1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S1. Synthetic procedure of drug-linker MTL1 (A) and 1H-NMR spectrum of MTL1 (B).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S1. Synthetic procedure of drug-linker MTL1 (A) and 1H-NMR spectrum of MTL1 (B).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Table S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.